1. Home
  2. ATER vs BOLT Comparison

ATER vs BOLT Comparison

Compare ATER & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aterian Inc.

ATER

Aterian Inc.

HOLD

Current Price

$0.92

Market Cap

10.3M

ML Signal

HOLD

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

HOLD

Current Price

$5.51

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATER
BOLT
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.3M
11.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ATER
BOLT
Price
$0.92
$5.51
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$34.00
AVG Volume (30 Days)
100.8K
32.2K
Earning Date
11-13-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$78,450,000.00
$5,195,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.65
$4.41
52 Week High
$3.50
$12.60

Technical Indicators

Market Signals
Indicator
ATER
BOLT
Relative Strength Index (RSI) 65.90 62.03
Support Level $0.65 $5.11
Resistance Level $0.90 $5.45
Average True Range (ATR) 0.06 0.28
MACD 0.03 0.11
Stochastic Oscillator 76.93 94.50

Price Performance

Historical Comparison
ATER
BOLT

About ATER Aterian Inc.

Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Share on Social Networks: